Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis

Overview of attention for article published in Frontiers in oncology, January 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#49 of 22,805)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 20 news outlets

twitter: 2 X users

Citations

dimensions_citation: 79 Dimensions

Readers on

mendeley: 49 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 20 news stories from 20 outlets.

AMGEN : BeiGene Announces the Approval in China of KYPROLIS (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

MarketScreener, 12 Jul 2021

BEIJING & CAMBRIDGE, Mass. - (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and…

BeiGene Announces the Approval in China of KYPROLIS (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

FirstWord Pharma, 09 Jul 2021

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused…

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

Biospace, 09 Jul 2021

July 9, 2021 04:00 UTC BEIJING

BeiGene Announces the Approval in China of KYPROLIS� (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

gurufocus, 09 Jul 2021

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 16 additional news stories.